Sydney, Australia - As the fourth conference in the HIV Pathogenesis, Treatment and Prevention series, IAS 2007 will feature reports on the latest developments in the areas of basic, clinical and prevention science.
The scientific programme of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention aims to provide new insights into HIV disease development, prevention and care that can lead to novel research directions and help translate theoretic advances into clinical practice and prevention programmes. Comprised of experts from around the world, the Scientific Programme Committee is committed to ensuring that the IAS 2007 programme will address the most timely and relevant scientific issues of the day, including the challenge of expanding treatment in resource-limited settings and the implications of emerging research on public and individual health.
The abstract-driven programme will feature state-of-the-art research in three broad areas: basic, clinical and prevention science. The basic sciences track will focus on virology, immunology, pathogenesis and preclinical research into drugs and vaccines. The clinical sciences track will cover the spectrum from treatment and low-cost monitoring in resource limited settings to new treatments, strategies and advanced approaches to HIV care and treatment across specific populations. The biomedical prevention track will focus on strategies for preventing HIV transmission that have a biomedical basis, such as vaccines, microbicides, chemoprophylaxis and substitution therapy for drug dependence.
In addition to abstract-driven sessions, the conference will offer daily plenary sessions featuring distinguished researchers, scientific leaders and clinical experts. Other non-abstract driven sessions include symposia, offering keynote addresses or presentations of outstanding abstracts, and bridging sessions, which will provide an opportunity for a multi-disciplinary discussion of a single issue from a variety of viewpoints.
Track A: HIV Basic Science
This track will encompass all aspects of fundamental HIV biology and the host response to HIV. Areas of focus will include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, co-infection, and progress in animal models. Pre-clinical vaccine, microbicide and drug development will be important themes of this track.
TRACK B: Clinical Research, Treatment and Care
This track will highlight the latest research findings, complexities and controversies related to the diagnosis, natural history and management of HIV infection; prevention, diagnosis and treatment of opportunistic infections; co-infection and other co-morbidities; antiretroviral therapy and immunotherapy. Issues for discussion related to antiretroviral therapy will include new drug therapies, pharmacokinetics, drug interactions, adherence, short- and long-term adverse events, clade types and drug resistance. Approaches to treatment, care and support in specific populations including infants and children, adolescents, women (including prevention of mother-to-child transmission), marginalized groups and innovations related to diagnosis and to provision of HIV care in resource-limited settings will be addressed.
TRACK C: Biomedical Prevention
This track will focus on HIV/AIDS prevention research and issues related to the design, implementation and evaluation of prevention programmes. It will include examination of methodological and programmamatic advances in the continuum of prevention research, particularly best practices in HIV prevention for vulnerable populations in resource-limited settings. Strategies to increase HIV prevention capacity, approaches to translate prevention research into practice, efforts to promote preparedness for biomedical prevention technologies, and research on new prevention approaches including microbicides, vaccines, pre-and post exposure prophylaxis, circumcision and other methods will be presented.
International AIDS Society
Ch. de l’Avanchet 33
P O Box 20
Phone: +41-(0)22-7 100 800
Fax: +41-(0)22-7 100 899